31 Mar 2021
Assets1,182.55
Total Income630.75
Profit After Tax234.89
NET Worth999.37
Total Borrowing86.35
Open 4th Aug 2023 · Close 8th Aug 2023 · Listing 18th Aug 2023
The shares listed at ₹900.05, a 21.46% move from the issue price. Concord Biotech is a Mainboard IPO with an issue size of ₹1,550.52 crore, proposed for listing on BSE, NSE. The offer opens on 4th Aug 2023 and closes on 8th Aug 2023. The issue structure includes an offer-for-sale component of ₹1,550.52 crore. The current listing schedule points to 18th Aug 2023.
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 20 | ₹14,820 |
| KPI |
|---|
| ROE |
| ROCE |
| RoNW |
| PAT Margin |
| Expense | Amount |
|---|---|
| Book Running Lead Managers' fees including underwriting commission | ₹33.02 Cr |
| Commission/processing fee for SCSB, Sponsor Banks and Bankers to the Offer. Brokerage, underwriting commission and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs(2)(3)(4)(5) | ₹5.43 Cr |
| Fees payable to the Registrar to the Offer | ₹0.28 Cr |
| Others | — |
| Auditor, independent chartered accountant, industry expert, intellectual property consultant, etc. | ₹5.68 Cr |
| Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | ₹4.84 Cr |
| Printing and stationery | ₹1.49 Cr |
| Advertising and marketing expenses | ₹5.48 Cr |
| Fees payable to legal counsels | ₹9.04 Cr |
| Miscellaneous | ₹2.33 Cr |